Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Vamifeport (VIT-2763) in Sickle Cell Disease
NCT04817670Phase 2Completed
- Sponsor
- CSL Vifor
- Start
- Nov 2021
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of vamifeport in sickle cell disease (SCD), sponsored by CSL Vifor. Started Nov 2021; status: completed.
02
Drugs
vamifeport
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT04817670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04817670.